Optical Coherence Tomography (OCT) in Retinal Vasculitis
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology, Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | January 2014 |
| End Date: | December 2019 |
| Contact: | Denny Romfh |
| Email: | romfhd@ohsu.edu |
| Phone: | 503-494-4351 |
Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Retinal Vasculitis
Retinal vasculitis is a sight-threatening inflammation that involves the blood vessels of the
retina, the tissue that lines the inside of the eye. This inflammation may occur on its own
or as a result of an infectious, cancerous, or inflammatory disorder.
Optical coherence tomography (OCT) is an imaging technology that can perform non-contact
cross-sectional imaging of retinal and choroidal tissue structure in real time. It is similar
to ultrasound imaging, except that OCT measures the intensity of reflected light rather than
sound waves.
The purpose of this study is to see if non-invasive OCT technology can diagnose retinal
vasculitis as well as the more invasive fluorescein angiography, which requires an injection
of dye into the vein of an arm of a patient. The study will also compare the mapping of blood
vessels (angiography) and loss of blood flow (ischemia) by fluorescein angiography and OCT.
retina, the tissue that lines the inside of the eye. This inflammation may occur on its own
or as a result of an infectious, cancerous, or inflammatory disorder.
Optical coherence tomography (OCT) is an imaging technology that can perform non-contact
cross-sectional imaging of retinal and choroidal tissue structure in real time. It is similar
to ultrasound imaging, except that OCT measures the intensity of reflected light rather than
sound waves.
The purpose of this study is to see if non-invasive OCT technology can diagnose retinal
vasculitis as well as the more invasive fluorescein angiography, which requires an injection
of dye into the vein of an arm of a patient. The study will also compare the mapping of blood
vessels (angiography) and loss of blood flow (ischemia) by fluorescein angiography and OCT.
Inclusion Criteria:
- Diagnosis of retinal vasculitis
Exclusion Criteria:
- Inability to give informed consent.
- Inability to complete the qualifying study tests within a 30 day period from date of
enrollment
- Significant renal disease, defined as a history of chronic renal failure requiring
dialysis or kidney transplant.
- A prior history of reaction to fluorescein or other dyes.
- A condition that, in the opinion of the investigator, would preclude participation in
the study (e.g. unstable medical status including blood pressure, cardiovascular
disease, and glycemic control).
- Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood
pressure is brought below 180/110 by anti-hypertensive treatment, subject can become
eligible.
- Systemic anti-vascular endothelial growth factor (VEGF) or pro-VEGF treatment within 4
months prior to treatment.
- Women of child-bearing potential: pregnant or lactating or intending to become
pregnant within the next 12 months due to unknown safety of fluorescein angiography.
- Prior panretinal photocoagulation (PRP) or focal laser that would alter the macular
perfusion and retinovascular features.
- Inability to maintain stable fixation for OCT imaging.
- Other ocular condition is present such that, in the opinion of the investigator, may
alter the retinal perfusion.
- An ocular condition is present that, in the opinion of the investigator, might affect
or alter visual acuity during the course of the study (i.e. cataract)
- Substantial cataract that, in the opinion of the investigator, is likely to decrease
visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or
worse if the eye was otherwise normal).
- Media opacity or otherwise that would prevent either fixation or ability to obtain
adequate images as determined by the examiner.
- History of major ocular surgery (including vitrectomy, cataract extraction, scleral
buckle, any intraocular surgery, etc) within prior 4 months.
We found this trial at
1
site
Click here to add this to my saved trials
